Jicka

The Med-Tech Big Data Revolution

做多
NYSE:FIT   None
Summary: Fitbit is in the early stages of its pivot from consumer products to med-tech. It has the distribution, sales, and brand recognition to position itself as a frontrunner in the med-tech big data revolution.

The main reason I think this is a huge sleeper is Fitbit is on the verge of switching to a SaaS company with recurring revenue. Key partnerships also give it a huge chance of being first.

In December 2017 Stockfish Chess AI was beaten by Googles AlphaZero's deep learning algorithm after it taught itself to play in only 4 hours. Stockfish searches 70 Million positions, Googles AlphaZero only 80 000. Alphazero won with 28 wins 72 draws 0 losses.

We are on the cusp of a biotech and infotech revolution and Fitbit is a company ready to take advantage.

  • Google partnerships
  • Multi year uptrend in R&D (and double the spend compared to Garmin)
  • Recurring non-device revenue and big customers like insurance


Thesis: Starting with the big picture on a weekly time frame, we see this is a previous momentum stock that has clearly based. Most attractive is it clearly broke out on huge volume before retesting. Are we seeing disbeleif?

This is a long term fundamental play. Next I will look at it from a closer perspective for entry and exit and confirmation strategies.

Exit Point / Timeframe: Long term fundamental growth play

Disclaimer: I am not a financial adviser and this is not financial advice. Trade at your own risk.

免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。